What is Veradermics?
Veradermics is a biopharmaceutical firm operating at the clinical stage, dedicated to pioneering novel, non-hormonal therapeutic solutions for a range of dermatologic and aesthetic ailments. The company's primary focus is on the development of oral therapies aimed at addressing hair regrowth, a significant area within the dermatology market. The recent enterprise-level funding indicates strong investor confidence in Veradermics' scientific approach and its potential to capture a substantial market share in the competitive biopharmaceutical landscape.
How much funding has Veradermics raised?
Veradermics has raised a total of $616.3M across 4 funding rounds:
Series B
$75M
Series C
$150M
Private Equity
$135M
IPO
$256.3M
Series B (2024): $75M with participation from PhiFund Ventures, J.W. Childs Associates, Connecticut Innovations, Osage University Partners, Longitude Capital, Surveyor Capital, and Suvretta Capital Management
Series C (2025): $150M led by Suvretta Capital Management, Viking Global Investors, Columbia Threadneedle Investments US, Infinitium, SR One, Longitude Capital, LifeSci Venture Partners, Invus, and Marshall Wace
Private Equity (2025): $135M, investors not publicly disclosed
IPO (2026): $256.3M featuring Lilly and Wellington Management
Key Investors in Veradermics
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Wellington Management
Wellington Management Company, LLP is a global, independent investment management firm based in Boston, Massachusetts. It provides institutional clients with portfolio management, research, and tailored investment solutions across equities, fixed income, multi-asset, and alternative strategies.
Suvretta Capital Management
Suvretta Capital Management, LLC operates as an investment management company. The Company offers capital management, financial planning, and advisory services. Suvretta Capital Management serves customers in the State of New York.
What's next for Veradermics?
With the recent influx of major strategic investment, Veradermics is poised to accelerate its development pipeline, potentially moving its lead oral hair regrowth therapy closer to commercialization. This significant capital infusion will likely support expanded clinical trials, manufacturing scale-up, and further research into its non-hormonal treatment modalities. The company's trajectory suggests a move towards later-stage development and potential market entry, positioning it as a key player in the specialized field of dermatologic and aesthetic medicine.
See full Veradermics company page
